Rick Schnellmann, PhD
Rick G. Schnellmann, PhD, is dean of the University of Arizona College of Pharmacy. A leading pharmacologist, researcher and drug discovery entrepreneur, he joined the UA in August 2016 from the Medical University of South Carolina.
Dr. Schnellmann earned his doctorate in pharmacology and toxicology from the University of Arizona Colleges of Pharmacy and Medicine in 1984. At the South Carolina College of Pharmacy at the Medical University of South Carolina (MUSC) in Charleston, he was eminent scholar and distinguished university professor and was chair of the college’s Department of Drug Discovery and Biomedical Sciences from 2001 to 2015. During his tenure as chair, Dr. Schnellmann assisted in the merger of the colleges of pharmacy at the University of South Carolina and MUSC, facilitating the transition to distance education on campuses 100 miles apart. Under his guidance, his department’s NIH grant funding increased, and in 2014 the school was ranked 11th in NIH funding to colleges of pharmacy.
Dr. Schnellmann’s research is focused on identifying and developing drugs to treat acute kidney injury, diabetic kidney disease, stroke, spinal cord injury and Parkinson’s disease. His research has been funded continuously since 1987 and includes NIH grant funding totaling more than $30 million. He has been instrumental in founding three MUSC spin-off biotechnology companies focused on drug discovery and development, including a drug for acute kidney injury, molecular compounds that could lead to new treatment for kidney failure and a compound being testing for treatment of retinitis pigmentosa.
He has a strong commitment to education and mentoring future researchers. He has taught pharmacology and toxicology to pharmacy, medical and veterinary students and has served on the Society of Toxicology Education Committee and the Subcommittee on Minority Education Initiatives. In 2013, Dr. Schnellmann received the Society’s Education Award for “his distinguished teaching and training of toxicologists and for his significant contributions to education in the broad field of toxicology.”
Dr. Schnellmann was the editor of the Journal of Pharmacology and Experimental Therapeutics from 2004 to 2009. He also has served as associate editor of the American Journal of Physiology and Toxicology and Applied Pharmacology. He has published more than 180 peer-reviewed publications and reviews and authored more than 28 book chapters. Dr. Schnellmann received a Bachelor of Science degree in pharmacy from St. Louis College of Pharmacy, and completed a postdoctoral fellowship in renal toxicology at Duke University Medical Center in Durham, N.C.
BS, Pharmacy, St. Louis College of Pharmacy, St. Louis, Missouri, 1980
PhD, Pharmacology and Toxicology, University of Arizona, Tucson, Arizona, 1984
Postdoctoral Fellowship, Renal Toxicology, Duke University, Durham, N.C,
Collier JB, Whitaker RM, Eblen ST, Schnellmann RG. Rapid Renal Regulation of Peroxisome Proliferator-activated Receptor γ Coactivator-1α by Extracellular Signal-Regulated Kinase 1/2 in Physiological and Pathological Conditions.J Biol Chem. 2016 Dec 23;291(52):26850-26859
Gibbs WS, Weber RA, Schnellmann RG, Adkins DL. Disrupted mitochondrial genes and inflammation following stroke.Life Sci. 2016 Dec 1;166:139-148.
Krishnasamy Y, Ramshesh VK, Gooz M, Schnellmann RG, Lemasters JJ, Zhong Z. Ethanol and High Cholesterol Diet Causes Severe Steatohepatitis and Early Liver Fibrosis in Mice.PLoS One. 2016 Sep 27;11(9):e0163342.
Cameron RB, Beeson CC, Schnellmann RG. Development of Therapeutics That Induce Mitochondrial Biogenesis for the Treatment of Acute and Chronic Degenerative Diseases.J Med Chem. 2016 Dec 8;59(23):10411-10434.
Harmon JL, Gibbs WS, Whitaker RM, Schnellmann RG, Adkins DL. Striatal Mitochondrial Disruption following Severe Traumatic Brain Injury.J Neurotrauma. 2017 Jan 15;34(2):487-494.
Rehman H, Liu Q, Krishnasamy Y, Shi Z, Ramshesh VK, Haque K, Schnellmann RG, Murphy MP, Lemasters JJ, Rockey DC, Zhong Z. The mitochondria-targeted antioxidant MitoQ attenuates liver fibrosis in mice.Int J Physiol Pathophysiol Pharmacol. 2016 Apr 25;8(1):14-27.
Smith JA, Mayeux PR, Schnellmann RG. Delayed Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Inhibition by Trametinib Attenuates Systemic Inflammatory Responses and Multiple Organ Injury in Murine Sepsis.Crit Care Med. 2016 Aug;44(8):e711-20.
Harmon JL, Wills LP, McOmish CE, Demireva EY, Gingrich JA, Beeson CC, Schnellmann RG. 5-HT2 Receptor Regulation of Mitochondrial Genes: Unexpected Pharmacological Effects of Agonists and Antagonists.J Pharmacol Exp Ther. 2016 Apr;357(1):1-9.
Dupre TV, Doll MA, Shah PP, Sharp CN, Kiefer A, Scherzer MT, Saurabh K, Saforo D, Siow D, Casson L, Arteel GE, Jenson AB, Megyesi J, Schnellmann RG, Beverly LJ, Siskind LJ. Suramin protects from cisplatin-induced acute kidney injury.Am J Physiol Renal Physiol. 2016 Feb 1;310(3):F248-58.
Whitaker RM, Corum D, Beeson CC, Schnellmann RG. Mitochondrial Biogenesis as a Pharmacological Target: A New Approach to Acute and Chronic Diseases.Annu Rev Pharmacol Toxicol. 2016;56:229-49.
Liu Q, Krishnasamy Y, Rehman H, Lemasters JJ, Schnellmann RG, Zhong Z. Disrupted Renal Mitochondrial Homeostasis after Liver Transplantation in Rats.PLoS One. 2015 Oct 19;10(10):e0140906.
Alhasson F, Dattaroy D, Das S, Chandrashekaran V, Seth RK, Schnellmann RG, Chatterjee S. NKT cell modulates NAFLD potentiation of metabolic oxidative stress-induced mesangial cell activation and proximal tubular toxicity.Am J Physiol Renal Physiol. 2016 Jan 1;310(1):F85-F101.
Whitaker RM, Stallons LJ, Kneff JE, Alge JL, Harmon JL, Rahn JJ, Arthur JM, Beeson CC, Chan SL, Schnellmann RG. Urinary mitochondrial DNA is a biomarker of mitochondrial disruption and renal dysfunction in acute kidney injury.Kidney Int. 2015 Dec;88(6):1336-1344.
Subathra M, Korrapati M, Howell LA, Arthur JM, Shayman JA, Schnellmann RG, Siskind LJ. Kidney glycosphingolipids are elevated early in diabetic nephropathy and mediate hypertrophy of mesangial cells.Am J Physiol Renal Physiol. 2015 Aug 1;309(3):F204-15.
Wills LP, Beeson GC, Hoover DB, Schnellmann RG, Beeson CC. Assessment of ToxCast Phase II for Mitochondrial Liabilities Using a High-Throughput Respirometric Assay.Toxicol Sci. 2015 Aug;146(2):226-34.
Seremwe M, Schnellmann RG, Bollag WB. Calpain-10 Activity Underlies Angiotensin II-Induced Aldosterone Production in an Adrenal Glomerulosa Cell Model.Endocrinology. 2015 Jun;156(6):2138-49.
Liu Q, Rehman H, Krishnasamy Y, Schnellmann RG, Lemasters JJ, Zhong Z. Improvement of liver injury and survival by JNK2 and iNOS deficiency in liver transplants from cardiac death mice.J Hepatol. 2015 Jul;63(1):68-74.
Sutter AG, Palanisamy AP, Ellet JD, Schmidt MG, Schnellmann RG, Chavin KD. Intereukin-10 and Kupffer cells protect steatotic mice livers from ischemia-reperfusion injury.Eur Cytokine Netw. 2014 Oct-Dec;25(4):69-76.
Whitaker RM, Korrapati MC, Stallons LJ, Jesinkey SR, Arthur JM, Beeson CC, Zhong Z, Schnellmann RG. Urinary ATP Synthase Subunit β Is a Novel Biomarker of Renal Mitochondrial Dysfunction in Acute Kidney Injury.Toxicol Sci. 2015 May;145(1):108-17.
Smith JA, Stallons LJ, Collier JB, Chavin KD, Schnellmann RG. Suppression of mitochondrial biogenesis through toll-like receptor 4-dependent mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signaling in endotoxin-induced acute kidney injury.J Pharmacol Exp Ther. 2015 Feb;352(2):346-57.